Evaluating immune correlates in HIV type 1 vaccine efficacy trials: What RV144 may provide

AIDS Research and Human Retroviruses

Volumn 28, Issue 4, 2012, Pages 400-404

  Rolland, Morgane ^a   Gilbert, Peter ^b  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CORRELATIONAL STUDY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MEDICAL RESEARCH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VACCINATION;

AIDS VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; MALE; TERMINOLOGY AS TOPIC;

EID: 84859166440     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0240     Document Type: Article

References (13)

1. Prentice RL: Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989;8(4):431-440.
2. Frangakis CE and Rubin DB: Principal stratification in causal inference. Biometrics 2002;58(1):21-29.
3. Qin L, Gilbert PB, et al.: A framework for assessing immu-nological correlates of protection in vaccine trials. J Infect Dis 2007;196(9):1304-1312.
4. Plotkin SA: Vaccines: Correlates of vaccine-induced immunity. Clin Infect Dis 2008;47(3):401-409.
5. Borgan, O., et al.: Exposure stratified case-cohort designs. Lifetime Data Anal 2000;6(1):39-58.
6. Gilbert, P.B., et al.: Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005;191(5):666-677.
7. Forthal, D.N., et al.: Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007;178(10):6596-6603.
8. Follmann D: Augmented designs to assess immune response in vaccine trials. Biometrics 2006;62(4):1161-1169.
9. Gilbert PB, Qin L, et al.: Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med 2008;27(23):4758-4778.
10. Qin L, Gilbert PB, et al.: Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the cox model. Ann Appl Stat 2008;2(1):386-407.
11. Gilbert PB and Hudgens MG: Evaluating candidate principal surrogate endpoints. Biometrics 2008;64(4):1146-1154.
12. Gilbert PB, Qin L, et al.: Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development.' Stat Med 2009; 28(4):716-719.
13. Wolfson J and Gilbert P: Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials. Biometrics 2020;66(4):1153-1161.